Table 2. Clinical and biologic... | American Society of Hematology

Table 2.

Clinical and biologic characteristics of 139 patients with TEL/AML1 gene fusion-negative and -positive B-lineage ALL with in vitro resistance data

TEL/AML1	Negative n (%)	Positive n (%)	P
Sex
Male	59 (66)	28 (57)	.327
Female	31 (34)	21 (43)
Median age (months, range)	58 (3-191)	57 (25-179)	.783
WBC ×10⁹/L
<50	76 (84)	40 (82)	.670
>50	14 (16)	9 (18)
Immunophenotype
c/preB	85 (94)	49 (100)	.161^*
proB	5 (6)	—
DNA index
<1.16	50 (71)	35 (97)	.001^†
1.16-1.35	18 (25)	—
>1.35	3 (4)	1 (3)
Unknown	19	13

TEL/AML1	Negative n (%)	Positive n (%)	P
Sex
Male	59 (66)	28 (57)	.327
Female	31 (34)	21 (43)
Median age (months, range)	58 (3-191)	57 (25-179)	.783
WBC ×10⁹/L
<50	76 (84)	40 (82)	.670
>50	14 (16)	9 (18)
Immunophenotype
c/preB	85 (94)	49 (100)	.161^*
proB	5 (6)	—
DNA index
<1.16	50 (71)	35 (97)	.001^†
1.16-1.35	18 (25)	—
>1.35	3 (4)	1 (3)
Unknown	19	13

Percentages expressed excluding the missing cases. Pvalues determined by χ² test and Mann-Whitney U(age).

c/preB versus proB; Fisher exact test.

Non-hyperdiploid (DNA index <1.16 and >1.35) versus hyperdiploid.